Compositions and methods for human metapneumovirus monoclonal antibodies
US8492097B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 24, 2006 |
| Grant date | Jul 23, 2013 |
| Priority date | — |
| Expiry date | Mar 2, 2027 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2469/10
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention discloses specific human metapneumovirus monoclonal antibodies. The antibody is at least two-fold less reactive with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Further, the antibody is at least two-fold more reactive with a human metapneumovirus (i.e., for example, Type A or Type B) than with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Consequently, these novel antibodies are useful as a clinical diagnostic agent, especially when using fresh nasopharengeal aspirates. The invention also contemplates numerous diagnostic platforms that together with the novel antibodies can support economical, fast, and highly selective detection and identification of clinical inoculum samples.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.